Private equity firms Warburg Pincus and CVC Capital Partners have shown interest in acquiring a stake in Orbicular Pharma, a specialty pharmaceutical company. The potential deal could value Orbicular Pharma at up to $1.5 billion, according to livemint.com. The company has appointed Jefferies as its advisor for the stake sale process.
Orbicular Pharma initiated the stake sale by mandating Jefferies to manage the transaction. The involvement of two major private equity players, Warburg Pincus and CVC Capital, signals strong investor confidence in the specialty pharma sector. The firms are currently evaluating the opportunity as Orbicular Pharma seeks to leverage the deal to support its growth plans.
The interest from Warburg Pincus and CVC Capital highlights the increasing appetite for investments in specialty pharmaceutical companies, which have shown resilience and growth potential. Comparable deals in the sector have attracted significant capital, reflecting the strategic importance of pharma firms with niche product portfolios. The valuation of $1.5 billion places Orbicular Pharma among the notable mid-sized specialty pharma companies attracting private equity attention.
Orbicular Pharma's stake sale process is ongoing, with Jefferies managing the advisory role. The final valuation and deal structure will become clearer as negotiations progress, with market watchers closely tracking the outcome given the high-profile nature of the investors involved.